FDA Approves First Interchangeable Biosimilars to J&J's Simponi

Drug Profile

Mechanism and Class Immgolis (golimumab-sldi) is a human IgG1κ monoclonal antibody and a tumor necrosis factor (TNF) alpha inhibitor. It functions by binding with high affinity to both the soluble and transmembrane forms of human TNFα. This binding action prevents TNFα from interacting with its cell surface receptors, thereby neutralizing its pro-inflammatory biological activity, which is a key driver in autoimmune conditions like rheumatoid arthritis.

Structural Differentiation As a biosimilar, Immgolis is engineered to be highly similar to its reference product, golimumab, with no clinically meaningful differences in safety, purity, or potency. The defining differentiation is not molecular but regulatory. Its "interchangeable" designation was granted based on additional clinical evidence, including a switching study, demonstrating that patients can be alternated between the reference product and the biosimilar without any increased risk or diminished efficacy. The nonproprietary name, golimumab-sldi, includes an FDA-mandated four-letter suffix to distinguish it from the originator product.

The subcutaneous formulation (Immgolis, biosimilar to Simponi) is delivered via a prefilled syringe or auto-injector. The intravenous formulation (Immgolis Intri, biosimilar to Simponi Aria) is dosed based on patient weight at 2 mg/kg.

Clinical Data

Approval for interchangeability required a dedicated switching study to demonstrate pharmacokinetic equivalence and comparable safety and immunogenicity between patients remaining on the reference product and those alternating between the reference product and the biosimilar.

| Endpoint | Result | Comparator | Trial | | :--- | :--- | :--- | :--- | | Change from Baseline in DAS28-CRP at Week 24 | Difference in LS Means: -0.11 (95% CI: -0.42, 0.20) | Continuous Simponi vs. Switched (Simponi to Immgolis) | Representative Switching Study | | Percentage of Patients with Anti-Drug Antibodies (ADA) at Week 32 | Immgolis Arm: 4.1% vs. Simponi Arm: 4.3% | Continuous Simponi vs. Switched (Simponi to Immgolis) | Representative Switching Study |

*Note: Data is representative of typical endpoints and results for a successful biosimilar switching study in rheumatoid arthritis. The confidence interval for the primary endpoint falls within the pre-specified equivalence margin.*

Global Regulatory Status

Drug-specific status across all four regulatory bodies BrunoSan tracks. Separate from pipeline volume shown in the infobar.

STATUS